The combination of ICIs (e.g., PD1 blockers) with cytokine antibodies (e.g., IL-6) could be a reasonable approach to improve the efficacy of immunotherapy for NSCLC. The gene discussed is IL6; the disease is non-small cell lung carcinoma.